Premium
Nonparametric Methods in Crossover Trials
Author(s) -
Öhrvik John
Publication year - 1998
Publication title -
biometrical journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.108
H-Index - 63
eISSN - 1521-4036
pISSN - 0323-3847
DOI - 10.1002/(sici)1521-4036(199811)40:7<771::aid-bimj771>3.0.co;2-k
Subject(s) - nonparametric statistics , crossover , wilcoxon signed rank test , test statistic , statistics , mathematics , goldfeld–quandt test , statistical power , statistic , statistical hypothesis testing , friedman test , crossover study , normality , resampling , test (biology) , asymptotic distribution , econometrics , z test , computer science , estimator , mann–whitney u test , artificial intelligence , medicine , paleontology , placebo , alternative medicine , pathology , biology
The crossover design is often used in biomedical trials since it eliminates between subject variability. This paper is concerned with the statistical analysis of data arising from such trials when assumptions like normality do not necessarily apply. Nonparametric analysis of the two‐period, two‐treatment design was first described by Koch in a paper 1972. The purpose of this paper is to study nonparametric methods in crossover designs with three or more treatments and an equal number of periods. The proposed test for direct treatment effects is based on within subject comparisons after removing a possible period effect. With only two treatments this test reduces to the twosided Wilcoxon signed rank test. By simulation experiments the validity of the significance level of the test when using the asymptotic distribution of the test statistic are manifested and the power against different alternatives illustrated. A test for first order carryover effects can be constructed by a straightforward generalization of the test proposed by Koch in 1972. However, since this test is based on between subject comparisons its power will be low. Our recommendation is to consider the crossover design rather than the parallel group design if the carryover effects are assumed to be neglible or positive and smaller then the direct treatment effects.